Parallax Volatility Advisers
ATRA icon

Parallax Volatility Advisers’s Atara Biotherapeutics ATRA Stock Holding History

Parallax Volatility Advisers’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,480
Closed -$977K – 2477
2015
Q4 		$977K Buy
+1,480
New +$1.12M ﹤0.01% 1291

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Parallax Volatility Advisers's ATRA Position: Q3 2019 in Review

Parallax Volatility Advisers sold out of Atara Biotherapeutics (ATRA) in Q3 2019, closing a stake of 4 shares — an estimated $2K sold.

Parallax Volatility Advisers first reported a position in ATRA in Q4 2015 and held it in 4 quarters. The position peaked at $311K in Q4 2015. 112 funds tracked by Wall St. Rank hold ATRA as of Q3 2019.

  • Parallax Volatility Advisers reported no remaining Atara Biotherapeutics position as of Q3 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 4 Atara Biotherapeutics shares in Q3 2019, an estimated $2K.
  • Parallax Volatility Advisers first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 4 quarters.
  • Parallax Volatility Advisers's Atara Biotherapeutics position peaked at $311K in Q4 2015.
  • 112 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2019.

Based on Parallax Volatility Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.